Advancing Treatment Strategies: A Comprehensive Review of Drug Delivery Innovations for Chronic Inflammatory Respiratory Diseases

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Aug 26

PMID 37631365

Authors

Junming Wang

Pengfei Wang

Yiru Shao

Daikun He

Affiliations

Soon will be listed here.

Abstract

Chronic inflammatory respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, present ongoing challenges in terms of effective treatment and management. These diseases are characterized by persistent inflammation in the airways, leading to structural changes and compromised lung function. There are several treatments available for them, such as bronchodilators, immunomodulators, and oxygen therapy. However, there are still some shortcomings in the effectiveness and side effects of drugs. To achieve optimal therapeutic outcomes while minimizing systemic side effects, targeted therapies and precise drug delivery systems are crucial to the management of these diseases. This comprehensive review focuses on the role of drug delivery systems in chronic inflammatory respiratory diseases, particularly nanoparticle-based drug delivery systems, inhaled corticosteroids (ICSs), novel biologicals, gene therapy, and personalized medicine. By examining the latest advancements and strategies in these areas, we aim to provide a thorough understanding of the current landscape and future prospects for improving treatment outcomes in these challenging conditions.

Citing Articles

Innovative approaches to asthma treatment: harnessing nanoparticle technology.

Goswami V, Sodhi K, Singh C Discov Nano. 2025; 20(1):21.

PMID: 39922940 PMC: 11807046. DOI: 10.1186/s11671-025-04211-z.

Lipid-Polymer Hybrid Nanoparticles in Microparticle-Based Powder: Evaluating the Potential of Methylprednisolone Delivery for Future Lung Disease Treatment via Inhalation.

Scialabba C, Craparo E, Bonsignore S, Cabibbo M, Cavallaro G Pharmaceutics. 2024; 16(11).

PMID: 39598577 PMC: 11597723. DOI: 10.3390/pharmaceutics16111454.

Elevated Fracture Risks in Patients Using Inhaled Corticosteroids: A Korean Nationwide Study.

Kong S, Jo A, Park C, Park K, Yun J, Kim J Endocrinol Metab (Seoul). 2024; 40(1):82-92.

PMID: 39212038 PMC: 11898311. DOI: 10.3803/EnM.2024.1990.

References

Werder R, Liu T, Abo K, Lindstrom-Vautrin J, Villacorta-Martin C, Huang J . CRISPR interference interrogation of COPD GWAS genes reveals the functional significance of desmoplakin in iPSC-derived alveolar epithelial cells. Sci Adv. 2022; 8(28):eabo6566. PMC: 9278866. DOI: 10.1126/sciadv.abo6566. View

Dorinsky P, DePetrillo P, DeAngelis K, Trivedi R, Darken P, Gillen M . Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. Clin Ther. 2020; 42(4):634-648. DOI: 10.1016/j.clinthera.2020.02.012. View

Davies J, Wainwright C, Canny G, Chilvers M, Howenstine M, Munck A . Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013; 187(11):1219-25. PMC: 3734608. DOI: 10.1164/rccm.201301-0153OC. View

Garcia-Fernandez A, Sancenon F, Martinez-Manez R . Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev. 2021; 177:113953. DOI: 10.1016/j.addr.2021.113953. View

Robbins P, Ghivizzani S . Viral vectors for gene therapy. Pharmacol Ther. 1998; 80(1):35-47. View

Kim D, Lee Y, Kim M, Lee S, Jon S, Lee S . Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma. Biomaterials. 2017; 140:37-44. DOI: 10.1016/j.biomaterials.2017.06.014. View

Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M . Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3):220-31. PMC: 4764353. DOI: 10.1056/NEJMoa1409547. View

Burgess J, Jonker M, Berg M, Ten Hacken N, Meyer K, van den Berge M . Periostin: contributor to abnormal airway epithelial function in asthma?. Eur Respir J. 2020; 57(2). DOI: 10.1183/13993003.01286-2020. View

Tsai M, Tsai Y, Lin Y, Hsu Y, Chen Y, Tsai M . IL-25 Induced ROS-Mediated M2 Macrophage Polarization via AMPK-Associated Mitophagy. Int J Mol Sci. 2022; 23(1). PMC: 8744791. DOI: 10.3390/ijms23010003. View

10.

Wollin L, Distler J, Redente E, Riches D, Stowasser S, Schlenker-Herceg R . Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019; 54(3). PMC: 6751387. DOI: 10.1183/13993003.00161-2019. View

11.

Bjursell M, Porritt M, Ericson E, Taheri-Ghahfarokhi A, Clausen M, Magnusson L . Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype. EBioMedicine. 2018; 29:104-111. PMC: 5925576. DOI: 10.1016/j.ebiom.2018.02.015. View

12.

Chapman K, Hurst J, Frent S, Larbig M, Fogel R, Guerin T . Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med. 2018; 198(3):329-339. DOI: 10.1164/rccm.201803-0405OC. View

13.

Anselmo A, Gokarn Y, Mitragotri S . Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2018; 18(1):19-40. DOI: 10.1038/nrd.2018.183. View

14.

Latorre M, Bacci E, Seccia V, Bartoli M, Cardini C, Cianchetti S . Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment. Ther Adv Respir Dis. 2020; 14:1753466620965151. PMC: 7716065. DOI: 10.1177/1753466620965151. View

15.

Chan A, De Simoni A, Wileman V, Holliday L, Newby C, Chisari C . Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022; 6:CD013030. PMC: 9188849. DOI: 10.1002/14651858.CD013030.pub2. View

16.

Sahib M, Darwis Y, Peh K, Abdulameer S, Tan Y . Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations. Int J Nanomedicine. 2011; 6:2351-66. PMC: 3205131. DOI: 10.2147/IJN.S25363. View

17.

Cooney A, Thornell I, Singh B, Shah V, Stoltz D, McCray Jr P . A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs. Am J Respir Cell Mol Biol. 2019; 61(6):747-754. PMC: 6890402. DOI: 10.1165/rcmb.2019-0006OC. View

18.

Tagalakis A, McAnulty R, Devaney J, Bottoms S, Wong J, Elbs M . A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer. Mol Ther. 2008; 16(5):907-15. DOI: 10.1038/mt.2008.38. View

19.

Raherison C, Girodet P . Epidemiology of COPD. Eur Respir Rev. 2010; 18(114):213-21. DOI: 10.1183/09059180.00003609. View

20.

Khan I, Hussein S, Houacine C, Sadozai S, Islam Y, Bnyan R . Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers. Int J Pharm. 2021; 598:120376. DOI: 10.1016/j.ijpharm.2021.120376. View